Table 1.
New therapies for IBD
| Treatment modality | Target | Type | Development status | Indication |
|---|---|---|---|---|
| New anti-TNF | ||||
| AVX-470 | TNF | Polyclonal anti-TNF AB | Phase 1 trials | Moderate-to-severe UC |
| Anti-adhesion agents | ||||
| AJM300 | α4 integrin | Oral α4 integrin antagonist | Phase 3 trials | UC |
| AMG 181 | α4β7 integrin MAdCAM | Monoclonal AB | Phase 2 trials | UC and CD |
| Etrolizumab | β7 integrin | Monoclonal AB | Phase 3 trials | UC and CD |
| PF-00547659 | MAdCAM-1 | Monoclonal AB | Phase 2 trials | UC and CD |
| Cytokine blockage | ||||
| Ustekinumab |
IL-12/IL-23 p40 subunit |
Monoclonal AB | FDA approved | CD |
| MEDI2070 (brazikumab) |
IL-23 P19 subunit |
Monoclonal AB | Phase 2b trials | CD |
| Risankizumab |
IL-23 P19 subunit |
Monoclonal AB | Phase 3 trials | UC and CD |
| JAK inhibitors | ||||
| Tofacitinib | Janus kinase | Oral JAK inhibitor |
FDA approved Phase 2b trials |
UC CD |
| Filgotinib | Janus kinase 1 | Oral JAK inhibitor | Phase 3 trials | CD |
| Upadacitinib | Janus kinase 1 | Oral JAK inhibitor | Phase 2 trials | CD |
| FMT | Gut microbiome | Feces | Phase 2 trials | UC |
| Anti-trafficking molecules | ||||
| Ozanimod (RPC1063) | S1P receptor agonist | Oral receptor modulator |
Phase 3 trials Phase 2 trials |
UC CD |
| TLR agonists | ||||
| DIMS0150 | TLR-9 | Oligonucleotide | Phase 3 trials | UC |
| Phosphatidylcholine | ||||
| LT-02 | Mucosal barrier | Oral phospholipid | Phase 3 trials | UC |
| PDE4 inhibitors | ||||
| Apremilast | Phosphodiesterase 4 | Oral PDE4 inhibitor | Phase 2 trial | UC |
| TGF beta | ||||
| Mongersen | SMAD7 | SMAD7 antisense oligonucleotide | Withdrawn from study | UC and CD |
| Corticosteroids | ||||
| Budesonide MMX | Glucocorticoid receptor | Second-generation corticosteroid | FDA approved | UC |
AB antibody, S1P sphingosine-1-phosphate